1. 945PA phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC). (23rd October 2018) Authors: O'Cearbhaill, R E; Wolfer, A; Disilvestro, P; O'Malley, D M; Sabbatini, P; Shohara, L; Schwarzenberger, P O; Ricciardi, T; Macri, M; Ryan, A; Venhaus, R R; Bryan, J K; Wong, P; Homicsko, K; Kandalaft, L; Rusakiewicz, S; Harari, A; Monk, B J; Coukos, G Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗